相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab
Ajay K. Gopal et al.
BLOOD (2008)
Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
Siao-Yi Wang et al.
BLOOD (2008)
Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models
Yongli Li et al.
JOURNAL OF IMMUNOLOGY (2007)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas
John M. Pagel et al.
CANCER RESEARCH (2007)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H. J. van Oers et al.
BLOOD (2006)
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group protocol S9911
Oliver W. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
RI Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma
JP Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Non-Hodgkin lymphoma: Diagnosis and treatment
SM Ansell et al.
MAYO CLINIC PROCEEDINGS (2005)
Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics
C Antonescu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma
JA Boucek et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
R Marcus et al.
BLOOD (2005)
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma:: long-term follow-up of a phase 1/2 study
LI Gordon et al.
BLOOD (2004)
A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells
MS Cragg et al.
BLOOD (2004)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab
RL Wahl
SEMINARS IN ONCOLOGY (2003)
Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma:: chemotherapy versus chemotherapy plus rituximab
M Herold et al.
ANNALS OF HEMATOLOGY (2003)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg et al.
BLOOD (2003)
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size
SA Sohaib et al.
BRITISH JOURNAL OF RADIOLOGY (2000)
分享论文
